



OPEN ACCESS

APPROVED BY
Frontiers Editorial Office,
Frontiers Media SA, Switzerland

*CORRESPONDENCE
Frontiers Editorial Office,
✉ research.integrity@frontiersin.org

RECEIVED 19 March 2025
ACCEPTED 19 March 2025
PUBLISHED 25 March 2025

CITATION
Frontiers Editorial Office (2025) Retraction:
Lycorine displays potent antitumor efficacy in
colon carcinoma by targeting STAT3.
Front. Pharmacol. 16:1596508.
doi: 10.3389/fphar.2025.1596508

COPYRIGHT
© 2025 Frontiers Editorial Office. This is an
open-access article distributed under the terms
of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/)
(CC BY). The use, distribution or reproduction in
other forums is permitted, provided the original
author(s) and the copyright owner(s) are
credited and that the original publication in this
journal is cited, in accordance with accepted
academic practice. No use, distribution or
reproduction is permitted which does not
comply with these terms.

Retraction: Lycorine displays potent antitumor efficacy in colon carcinoma by targeting STAT3

Frontiers Editorial Office*

A Retraction of the Original Research Article

[Lycorine Displays Potent Antitumor Efficacy in Colon Carcinoma by Targeting STAT3](#)

by Wu S, Qiu Y, Shao Y, Yin S, Wang R, Pang X, Ma J, Zhang C, Wu B, Koo S, Han L, Zhang Y, Gao X, Wang T and Yu H (2018). *Front. Pharmacol.* 9:881. doi: [10.3389/fphar.2018.00881](https://doi.org/10.3389/fphar.2018.00881)

The journal retracts the August 8 2018 article cited above.

Following publication, concerns were raised regarding the integrity of the images in the published figures. The authors failed to provide a satisfactory explanation during the investigation, which was conducted in accordance with Frontiers' policies. As a result, the data and conclusions of the article have been deemed unreliable, and the article has been retracted.

The authors did not provide a response to this retraction.